Alpha Teknova Inc
NASDAQ:TKNO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.29
9.76
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Alpha Teknova Inc
Alpha Teknova, Inc. manufactures cell culture media and supplements. The company is headquartered in Hollister, California and currently employs 231 full-time employees. The company went IPO on 2021-06-25. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Its processes enable it to manufacture and deliver custom, made-to-order products across all stages of development, including commercialization. The firm's processes are designed to handle as array of customer-requested inputs, which vary by volume, chemical formulation, quality specifications, container types, and transportation requirements, enabling use of its products across the scope of the life sciences market.
Alpha Teknova, Inc. manufactures cell culture media and supplements. The company is headquartered in Hollister, California and currently employs 231 full-time employees. The company went IPO on 2021-06-25. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Its processes enable it to manufacture and deliver custom, made-to-order products across all stages of development, including commercialization. The firm's processes are designed to handle as array of customer-requested inputs, which vary by volume, chemical formulation, quality specifications, container types, and transportation requirements, enabling use of its products across the scope of the life sciences market.
Revenue Growth: Teknova reported Q3 2025 revenue of $10.5 million, up 9% year-on-year, marking the fifth straight quarter of growth.
Lab Essentials Strength: Lab Essentials product sales rose 16% to $8.3 million, driven by higher revenue per customer and more customers.
Clinical Solutions Headwind: Clinical Solutions revenue fell 13% to $1.7 million due to lower revenue per customer, but customer count increased.
Gross Margin Recovery: Gross margin improved to 30.7% from 0.9% last year, rebounding from large nonrecurring charges in Q3 2024.
Net Loss Narrowed: Net loss was $4.3 million (negative $0.08 per share), an improvement from a $7.6 million loss (negative $0.15 per share) last year.
2025 Revenue Guidance: Full-year revenue outlook of $39–42 million reiterated; management expects to finish slightly below the midpoint due to ongoing Clinical Solutions softness.
Operational Efficiency: Ongoing process improvements and automation are expected to support growth to over $200 million in annual revenue without major new capital spending.
